Maduck Sean has filed 71 Form 4 transactions, all in a single company, Corcept Therapeutics (CORT). The pattern is one-sided: zero open-market purchases and roughly $31.7 million in total open-market sales. The only buys, valued at about $109,000, are compensation-related grants and option exercises, which are mechanical events rather than discretionary purchases.
The recent activity, spanning July through October 2026, shows a steady stream of sales. On October 2, Sean sold shares worth $1.02 million and $1.84 million, paired with an option exercise of $203,334. The prior day brought a smaller sale of $47,717. September 1 saw three sales totaling $2.86 million, alongside a $206,750 option exercise. August was heavier: sales of $3.15 million and $739,965 on August 25, $419,491 on August 14, $118,068 on August 10, and $2.33 million on August 3. July 1 had three sales worth $2.21 million combined. Each sale was matched with an option exercise of a much smaller value, and two tax-withholding transactions (code F) appeared in June and September.
The dollar values are large, but the structure is routine for an executive with stock options. Sales cluster on the first trading day of each month, which is a typical schedule for a 10b5-1 plan. The absence of any open-market purchases means Sean has not added shares with personal cash during this window. The net direction is clearly toward reducing holdings, with the October 2 transactions alone exceeding $2.8 million in sales.
AI-assisted summary